GPI-0100 is Avantogen’s lead adjuvanat-immunopotentiator, a key component of vaccines for boosting the immune response. The GPI-0100 adjuvant, which has been shown to significantly enhance the immune response with a...
- Mechanism
- Curator reviewed
A proprietary semi-synthetic saponin derivative, GPI-0100 acts by up-regulating the body's immune system and stimulating both humoral and an effective T-cell immunity with CTL production. Compared with other immune stimulatory saponins, GPI-0100 has superior stability and safety profile, making it an ideal candidate for the development of novel therapeutics or preventive vaccines.
- Primary indication
- Investigated for use/treatment in breast cancer, kidney cancer, leukemia (myeloid), melanoma, neuroblastoma, ovarian cancer, and prostate cancer.Curator reviewed
- Code names
- GPI-0100
Resolves to
What you can answer from here — as of April 02, 2025
Which companies are running trials of GPI-0100, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account